Other strategies tested to augment the effect of anti-GD2 mAbs with various combination therapies in neuroblastoma include Ch14.18 + irinotecan + temozolomide + GM-CSF [178], Hu14.18K322A + induction chemotherapy [179], Hu14.18-IL2 + expanded NK cells (NCT02573896), Ch14.18 + temozolomide + expanded γδ T cells (NCT05400603), Anti-GD2 CARs [180] and many others. The gene discussed is IL2; the disease is neuroblastoma.